Edrecolomab: Difference between revisions

	WikiDoc Resources for Edrecolomab
Articles
Most recent articles on Edrecolomab Most cited articles on Edrecolomab Review articles on Edrecolomab Articles on Edrecolomab in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Edrecolomab Images of Edrecolomab Photos of Edrecolomab Podcasts & MP3s on Edrecolomab Videos on Edrecolomab
Evidence Based Medicine
Cochrane Collaboration on Edrecolomab Bandolier on Edrecolomab TRIP on Edrecolomab
Clinical Trials
Ongoing Trials on Edrecolomab at Clinical Trials.gov Trial results on Edrecolomab Clinical Trials on Edrecolomab at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Edrecolomab NICE Guidance on Edrecolomab NHS PRODIGY Guidance FDA on Edrecolomab CDC on Edrecolomab
Books
Books on Edrecolomab
News
Edrecolomab in the news Be alerted to news on Edrecolomab News trends on Edrecolomab
Commentary
Blogs on Edrecolomab
Definitions
Definitions of Edrecolomab
Patient Resources / Community
Patient resources on Edrecolomab Discussion groups on Edrecolomab Patient Handouts on Edrecolomab Directions to Hospitals Treating Edrecolomab Risk calculators and risk factors for Edrecolomab
Healthcare Provider Resources
Symptoms of Edrecolomab Causes & Risk Factors for Edrecolomab Diagnostic studies for Edrecolomab Treatment of Edrecolomab
Continuing Medical Education (CME)
CME Programs on Edrecolomab
International
Edrecolomab en Espanol Edrecolomab en Francais
Business
Edrecolomab in the Marketplace Patents on Edrecolomab
Experimental / Informatics
List of terms related to Edrecolomab

Edrecolomab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	EpCAM (17-1A)
Clinical data
Trade names	Panorex
ATC code	L01XC01 (WHO) ;
Identifiers
CAS Number	156586-89-9 ;
ChemSpider	NA ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
(what is this?) (verify)

VisualWikitext

Revision as of 14:06, 7 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Edrecolomab (MAb17-1A, trade name Panorex) is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.

Preliminary studies had shown promise of a possible use in patients with stage III colorectal carcinoma (with metastasis to the lymph nodes).^[1]^[2] However, when put to a phase III study (2,761 patients) it did not provide any benefit when compared to conventional chemotherapeutic agents.^[3] No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.^[4]

Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer.

References

↑ Riethmüller G, Schneider-Gädicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet. 1994;343(8907):1177-83. PMID 7909866
↑ Fields AL, Keller AM, Schwartzberg L et al. Edrecolomab (17-1A antibody) in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study (abstract). Proc Am Soc Clin Oncol. 2002;21:128a.
↑ Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002;360(9334):671-7. doi:10.1016/S0140-6736(02)09836-7 PMID 12241873
↑ Colacchio TA, Niedzwicki D, Compton C, et al. Phase III trial of adjuvant immunotherapy with MoAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). Proc Am Soc Clin Oncol. 2004;23:251a.

Template:Extracellular chemotherapeutic agents Template:Monoclonals for tumors

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

Template:Antineoplastic-drug-stub

[Lancet1994-1] Riethmüller G, Schneider-Gädicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet. 1994;343(8907):1177-83. PMID 7909866

[Proc2002-2] Fields AL, Keller AM, Schwartzberg L et al. Edrecolomab (17-1A antibody) in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study (abstract). Proc Am Soc Clin Oncol. 2002;21:128a.

[3] Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002;360(9334):671-7. doi:10.1016/S0140-6736(02)09836-7 PMID 12241873

[stageII-4] Colacchio TA, Niedzwicki D, Compton C, et al. Phase III trial of adjuvant immunotherapy with MoAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). Proc Am Soc Clin Oncol. 2004;23:251a.

[1]

[2]

[3]

[4]

@@ Line 1: / Line 1: @@
-'''Edrecolomab''' (MAb17-1A) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, which is expressed on epithelial tissues and on various carcinomas. Preliminary studies had shown promise of a possible use in patients with colorectal carcinoma. However, when put to a phase III study (2,761 patients) it did not provide any benefit when compared to conventional chemotherapeutic agents
+{{Drugbox
-<ref>''Punt CJ et al, Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. The Lancet, Volume 360, Issue 9334, Pages 671-677''   [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12241873&query_hl=1&itool=pubmed_DocSum]
+| Verifiedfields = changed
-</ref>. It is important to mention that edrecolomab was well tolerated and as such research has now concentrated on whether it can be of any use in other forms of cancer.
+| verifiedrevid = 461092781
+| image =
+<!--Monoclonal antibody data-->
+| type = mab
+| mab_type = mab
+| source = o
+| target = [[EpCAM]] (17-1A)
+<!--Clinical data-->
+| tradename = Panorex
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
+| pregnancy_US = <!-- A / B            / C / D / X -->
+| pregnancy_category =
+| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
+| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
+| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
+| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
+| legal_status =
+| routes_of_administration =
+<!--Pharmacokinetic data-->
+| bioavailability =
+| protein_bound =
+| metabolism =
+| elimination_half-life =
+| excretion =
+<!--Identifiers-->
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = NA
+| CAS_number_Ref = {{cascite|changed|??}}
+| CAS_number = 156586-89-9
+| ATC_prefix = L01
+| ATC_suffix = XC01
+| PubChem =
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| DrugBank =
+<!--Chemical data-->
+| chemical_formula =
+| molecular_weight =
+}}
+__NOTOC__
+{{SI}}
+{{CMG}}
+==Overview==
+'''Edrecolomab''' (MAb17-1A, trade name '''Panorex''') is a mouse-derived [[monoclonal antibody]] targeting the cell-surface [[glycoprotein]] [[EpCAM]] (17-1A), which is expressed on [[epithelium|epithelial tissues]] and on various [[carcinoma]]s.
+Preliminary studies had shown promise of a possible use in patients with stage III [[colorectal carcinoma]] (with [[metastasis]] to the [[lymph nodes]]).<ref name="Lancet1994">Riethmüller G, Schneider-Gädicke E, Schlimok G ''et al.'' Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. ''Lancet''. 1994;'''343(8907)''':1177-83. PMID 7909866</ref><ref name="Proc2002">Fields AL, Keller AM, Schwartzberg L ''et al.'' Edrecolomab (17-1A antibody) in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study (abstract). ''Proc Am Soc Clin Oncol''. 2002;'''21''':128a.</ref> However, when put to a phase III study (2,761 patients) it did not provide any benefit when compared to conventional [[chemotherapy|chemotherapeutic]] agents.<ref>Punt CJ, Nagy A, Douillard JY ''et al.'' Edrecolomab alone or in combination with [[fluorouracil]] and [[folinic acid]] in the adjuvant treatment of stage III colon cancer: a randomised study. ''Lancet''. 2002;'''360(9334)''':671-7. {{DOI|10.1016/S0140-6736(02)09836-7}} PMID 12241873</ref> No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.<ref name="stageII">Colacchio TA, Niedzwicki D, Compton C, ''et al.'' Phase III trial of adjuvant immunotherapy with MoAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). ''Proc Am Soc Clin Oncol''. 2004;'''23''':251a.</ref>
+Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer.
 ==References==
-<references/>
+{{reflist|2}}
+{{Extracellular chemotherapeutic agents}}
+{{Monoclonals for tumors}}
-{{mousemonoclonals}}
+[[Category:Monoclonal antibodies for tumors]]
+[[Category:Drug]]
-[[Category:Monoclonal antibodies]]
+{{monoclonal-antibody-stub}}
-{{WikiDoc Help Menu}}
+{{antineoplastic-drug-stub}}
-{{WikiDoc Sources}}

Edrecolomab: Difference between revisions

Revision as of 14:06, 7 April 2015

Overview

References

Navigation menu